Literature DB >> 29042465

Thrombotic Microangiopathy and the Kidney.

Vicky Brocklebank1,2, Katrina M Wood3, David Kavanagh4,2.   

Abstract

Thrombotic microangiopathy can manifest in a diverse range of diseases and is characterized by thrombocytopenia, microangiopathic hemolytic anemia, and organ injury, including AKI. It can be associated with significant morbidity and mortality, but a systematic approach to investigation and prompt initiation of supportive management and, in some cases, effective specific treatment can result in good outcomes. This review considers the classification, pathology, epidemiology, characteristics, and pathogenesis of the thrombotic microangiopathies, and outlines a pragmatic approach to diagnosis and management.
Copyright © 2018 by the American Society of Nephrology.

Entities:  

Keywords:  Acute Kidney Injury; Anemia; Complement; Hemolytic; Purpura; Thrombotic Microangiopathies; Thrombotic Thrombocytopenic; atypical hemolytic uremic syndrome; glomerular disease; kidney

Mesh：

Substances：

Year:  2017        PMID： 29042465      PMCID： PMC5967417          DOI： 10.2215/CJN.00620117

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


  127 in total

Review 1.  Drug-induced thrombotic microangiopathy: incidence, prevention and management.

Authors:  R Pisoni; P Ruggenenti; G Remuzzi
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

2.  Eculizumab in severe Shiga-toxin-associated HUS.

Authors:  Anne-Laure Lapeyraque; Michal Malina; Véronique Fremeaux-Bacchi; Tobias Boppel; Michael Kirschfink; Mehdi Oualha; François Proulx; Marie-José Clermont; Françoise Le Deist; Patrick Niaudet; Franz Schaefer
Journal:  N Engl J Med       Date:  2011-05-25       Impact factor: 91.245

Review 3.  Scleroderma renal crisis and renal involvement in systemic sclerosis.

Authors:  Thasia G Woodworth; Yossra A Suliman; Wendi Li; Daniel E Furst; Philip Clements
Journal:  Nat Rev Nephrol       Date:  2016-09-19       Impact factor: 28.314

Review 4.  Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome.

Authors:  Phillip I Tarr; Carrie A Gordon; Wayne L Chandler
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

5.  A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group.

Authors:  J E Feinberg; S Hurwitz; D Cooper; F R Sattler; R R MacGregor; W Powderly; G N Holland; P D Griffiths; R B Pollard; M Youle; M J Gill; F J Holland; M E Power; S Owens; D Coakley; J Fry; M A Jacobson
Journal:  J Infect Dis       Date:  1998-01       Impact factor: 5.226

Review 6.  STEC-HUS, atypical HUS and TTP are all diseases of complement activation.

Authors:  Marina Noris; Federica Mescia; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2012-09-18       Impact factor: 28.314

7.  Pneumococcus-induced T-antigen activation in hemolytic uremic syndrome and anemia.

Authors:  Joel B Cochran; Valerie M Panzarino; Lanne Y Maes; Frederick W Tecklenburg
Journal:  Pediatr Nephrol       Date:  2004-01-09       Impact factor: 3.714

8.  Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes.

Authors:  Marie Scully; Mari Thomas; Mary Underwood; Henry Watson; Katherine Langley; Raymond S Camilleri; Amanda Clark; Desmond Creagh; Rachel Rayment; Vickie Mcdonald; Ashok Roy; Gillian Evans; Siobhan McGuckin; Fionnuala Ni Ainle; Rhona Maclean; William Lester; Michael Nash; Rosemary Scott; Patrick O Brien
Journal:  Blood       Date:  2014-05-23       Impact factor: 22.113

Review 9.  Atypical hemolytic uremic syndrome.

Authors:  David Kavanagh; Tim H Goodship; Anna Richards
Journal:  Semin Nephrol       Date:  2013-11       Impact factor: 5.299

10.  Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.

Authors:  Vicky Brocklebank; David Kavanagh
Journal:  Clin Kidney J       Date:  2017-05-08
View more
  74 in total

1.  The Differential Diagnosis and Treatment of Thrombotic Microangiopathies.

Authors:  Martin Bommer; Manuela Wölfle-Guter; Stephan Bohl; Florian Kuchenbauer
Journal:  Dtsch Arztebl Int       Date:  2018-05-11       Impact factor: 5.594

2.  The Benefits of Complement Measurements for the Clinical Practice.

Authors:  Anne Grunenwald; Lubka T Roumenina
Journal:  Methods Mol Biol       Date:  2021

3.  Atypical haemolytic uremic syndrome from multiple missenses to a full-blown disease.

Authors:  Filipe Santos Mira; Ana Luísa Nunes; Ana Rita Elvas; Nuno Oliveira
Journal:  BMJ Case Rep       Date:  2019-06-27

Review 4.  [The complement system-a "hot topic" not only for kidney diseases].

Authors:  Kerstin Amann; Christoph Daniel; Maike Büttner-Herold
Journal:  Pathologe       Date:  2020-05       Impact factor: 1.011

5.  Acute kidney injuries induced by thrombotic microangiopathy following severe hemorrhage in puerperants: a case series and literature review.

Authors:  Xu Wang; Chun-Yan Liu; Yue Yang; Gu-Ming Zou; Li Zhuo; Su-Hui Han; Wen-Ge Li
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

Review 6.  The role of complement in kidney disease.

Authors:  Jamie Willows; Matthew Brown; Neil S Sheerin
Journal:  Clin Med (Lond)       Date:  2020-03       Impact factor: 2.659

Review 7.  Pre-eclampsia: pathogenesis, novel diagnostics and therapies.

Authors:  Elizabeth A Phipps; Ravi Thadhani; Thomas Benzing; S Ananth Karumanchi
Journal:  Nat Rev Nephrol       Date:  2019-05       Impact factor: 28.314

Review 8.  Kidney injury and disease in patients with haematological malignancies.

Authors:  Frank Bridoux; Paul Cockwell; Ilya Glezerman; Victoria Gutgarts; Jonathan J Hogan; Kenar D Jhaveri; Florent Joly; Samih H Nasr; Deirdre Sawinski; Nelson Leung
Journal:  Nat Rev Nephrol       Date:  2021-03-30       Impact factor: 28.314

Review 9.  Chronic Allograft Injury.

Authors:  Eric Langewisch; Roslyn B Mannon
Journal:  Clin J Am Soc Nephrol       Date:  2021-04-05       Impact factor: 8.237

10.  Alternative complement pathway activation in thrombotic microangiopathy associated with lupus nephritis.

Authors:  Juan M Mejia-Vilet; Ismael A Gómez-Ruiz; Cristino Cruz; R Angélica Méndez-Pérez; Roque A Comunidad-Bonilla; Norma O Uribe-Uribe; Carlos A Nuñez-Alvarez; Luis E Morales-Buenrostro
Journal:  Clin Rheumatol       Date:  2020-11-10       Impact factor: 2.980
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.